FDA Steps Up Oversight Of Virtual Pharmaceutical Advertisements

FDA’s two complaints in the first two months of 2022 alone over inappropriate use of virtual marketing to promote drug products signal stakeholders could be right in expecting stepped up vigilance by FDA over drug makers’ growing use of social media and other forms of digital marketing to promote their products. After seeing hardly any FDA oversight of such advertising in 2021, drug industry stakeholders took notice when FDA in January complained to Eli Lilly and Company that its Instagram...